Gene Expression Profiling in PBMCs as a Tool for Prediction of Anakinra Responsiveness in Rheumatoid Arthritis
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The objective of the study is to identify and validate predictive markers of anakinra
responsiveness in RA patients by a transcriptomic approach.
Patients with active RA (ACR criteria) were given subcutaneous anakinra (100mg/d) 3
associated with metotrexate. Anakinra efficacy was evaluated at week 12, using the EULAR
response criteria.
A blood sample was collected just before the onset of anakinra treatment and total RNAs were
extracted from the peripheral blood mononuclear cells. The [33P] radiolabeled mRNAs were
hybridized (duplicate or triplicate) over a set of 10.000 human cDNA probes spotted at a high
density on nylon membranes. Data were normalized and filtered to allow the comparison between
RNA samples. Statistical analyses were performed with the R software and hierarchical
clustering was performed with the Cluster and Tree View softwares.
Details
Lead Sponsor:
University Hospital, Rouen
Treatments:
Interleukin 1 Receptor Antagonist Protein Methotrexate